Literature DB >> 7361718

Serum caffeine half-lives. Healthy subjects vs. patients having alcoholic hepatic disease.

B E Statland, T J Demas.   

Abstract

Results are presented describing serum caffeine half-lives for three healthy subjects and two patients having alcoholic hepatic disease. The mean serum caffeine half-life for the healthy subjects was 5.7 hours. One patient, a 35-year-old man who had alcoholic hepatic disease, had a serum half-life of 60 hours. The other patient, a 49-year-old woman having alcoholic hepatic disease had a serum half-life of 168 hours. The prolonged serum half-lives for the two patients are explained on the basis of compromised liver function. The serum half-life of caffeine was determined for the three healthy subjects when 25 mg diazepam was given one hour prior to the caffeine load. A significant difference was not found between the serum half-lives measured after diazepam was given and the serum half-life measured when diazepam was not given.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7361718     DOI: 10.1093/ajcp/73.3.390

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  17 in total

Review 1.  The impact of caffeine on vasodilator stress perfusion studies.

Authors:  Andre C Lapeyre; Tauqir Y Goraya; Donald L Johnston; Raymond J Gibbons
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

Review 2.  Performance-enhancing substances in sports: a review of the literature.

Authors:  Amit Momaya; Marc Fawal; Reed Estes
Journal:  Sports Med       Date:  2015-04       Impact factor: 11.136

Review 3.  Clinical pharmacokinetics of non-opiate abused drugs.

Authors:  U Busto; R Bendayan; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1989-01       Impact factor: 6.447

4.  Prognostic value of vasodilator response using rubidium-82 positron emission tomography myocardial perfusion imaging in patients with coronary artery disease.

Authors:  Punitha Arasaratnam; Masoud Sadreddini; Yeung Yam; Vinay Kansal; Sharmila Dorbala; Marcelo F Di Carli; Rob S Beanlands; Michael E Merhige; Brent A Williams; Emir Veledar; James K Min; Li Chen; Terrence D Ruddy; Guido Germano; Daniel S Berman; Leslee J Shaw; Benjamin J W Chow
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-11-27       Impact factor: 9.236

5.  Serum caffeine levels after 24 hours of caffeine abstention: observations on clinical patients undergoing myocardial perfusion imaging with dipyridamole or adenosine.

Authors:  A F Jacobson; M D Cerqueira; V Raisys; S Shattuc
Journal:  Eur J Nucl Med       Date:  1994-01

Review 6.  Cumulative neurobehavioral and physiological effects of chronic caffeine intake: individual differences and implications for the use of caffeinated energy products.

Authors:  Andrea M Spaeth; Namni Goel; David F Dinges
Journal:  Nutr Rev       Date:  2014-10       Impact factor: 7.110

7.  The effects of obesity and exercise on the pharmacokinetics of caffeine in lean and obese volunteers.

Authors:  G H Kamimori; S M Somani; R G Knowlton; R M Perkins
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

8.  Correlation of caffeine elimination and Child's classification in liver cirrhosis.

Authors:  A Holstege; M Staiger; K Haag; W Gerok
Journal:  Klin Wochenschr       Date:  1989-01-04

9.  The effect of drinking coffee and smoking cigarettes on the risk of cirrhosis associated with alcohol consumption. A case-control study. Provincial Group for the Study of Chronic Liver Disease.

Authors:  G Corrao; A R Lepore; P Torchio; M Valenti; G Galatola; A D'Amicis; S Aricó; F di Orio
Journal:  Eur J Epidemiol       Date:  1994-12       Impact factor: 8.082

10.  Acute effects of light and dark roasted coffee on glucose tolerance: a randomized, controlled crossover trial in healthy volunteers.

Authors:  Elin Rakvaag; Lars Ove Dragsted
Journal:  Eur J Nutr       Date:  2015-09-05       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.